U.S. Physical Therapy, Inc. (NYSE:USPH) Expected to Post Quarterly Sales of $130.01 Million

Brokerages forecast that U.S. Physical Therapy, Inc. (NYSE:USPHGet Rating) will announce $130.01 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for U.S. Physical Therapy’s earnings. The highest sales estimate is $132.33 million and the lowest is $126.61 million. U.S. Physical Therapy reported sales of $112.37 million during the same quarter last year, which indicates a positive year-over-year growth rate of 15.7%. The business is scheduled to issue its next earnings report before the market opens on Monday, January 1st.

On average, analysts expect that U.S. Physical Therapy will report full-year sales of $555.53 million for the current fiscal year, with estimates ranging from $552.00 million to $560.10 million. For the next financial year, analysts expect that the company will report sales of $582.46 million, with estimates ranging from $580.22 million to $584.50 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow U.S. Physical Therapy.

U.S. Physical Therapy (NYSE:USPHGet Rating) last released its earnings results on Thursday, February 24th. The company reported $0.73 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.69 by $0.04. The company had revenue of $129.83 million during the quarter, compared to analysts’ expectations of $128.62 million. U.S. Physical Therapy had a return on equity of 15.08% and a net margin of 6.77%. The business’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same period last year, the firm earned $1.08 EPS.

Several equities research analysts have recently commented on USPH shares. StockNews.com started coverage on U.S. Physical Therapy in a research note on Thursday, March 31st. They issued a “hold” rating for the company. Zacks Investment Research cut U.S. Physical Therapy from a “buy” rating to a “hold” rating in a research note on Wednesday, March 2nd. Finally, Barrington Research decreased their price objective on U.S. Physical Therapy from $144.00 to $123.00 in a research note on Friday, February 25th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $120.00.

NYSE USPH opened at $106.86 on Thursday. The stock has a fifty day moving average of $98.18 and a 200-day moving average of $98.36. The stock has a market capitalization of $1.39 billion, a P/E ratio of 44.16 and a beta of 1.35. U.S. Physical Therapy has a 52 week low of $84.43 and a 52 week high of $123.38. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.14 and a current ratio of 1.14.

The firm also recently announced a quarterly dividend, which was paid on Friday, April 8th. Shareholders of record on Monday, March 14th were paid a $0.41 dividend. This represents a $1.64 dividend on an annualized basis and a yield of 1.53%. This is a boost from U.S. Physical Therapy’s previous quarterly dividend of $0.38. The ex-dividend date of this dividend was Friday, March 11th. U.S. Physical Therapy’s payout ratio is presently 67.77%.

In other news, Director Harry S. Chapman sold 1,280 shares of the business’s stock in a transaction dated Thursday, March 17th. The stock was sold at an average price of $96.02, for a total value of $122,905.60. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Harry S. Chapman sold 3,320 shares of the business’s stock in a transaction dated Tuesday, March 15th. The shares were sold at an average price of $94.75, for a total value of $314,570.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 7,218 shares of company stock valued at $676,259. Insiders own 1.80% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Riverbridge Partners LLC raised its holdings in U.S. Physical Therapy by 10.8% during the first quarter. Riverbridge Partners LLC now owns 422,358 shares of the company’s stock worth $42,004,000 after acquiring an additional 41,012 shares in the last quarter. Boston Trust Walden Corp raised its holdings in U.S. Physical Therapy by 3.2% during the first quarter. Boston Trust Walden Corp now owns 450,455 shares of the company’s stock worth $44,798,000 after acquiring an additional 13,800 shares in the last quarter. Copeland Capital Management LLC raised its holdings in U.S. Physical Therapy by 25.8% during the first quarter. Copeland Capital Management LLC now owns 522,927 shares of the company’s stock worth $52,005,000 after acquiring an additional 107,170 shares in the last quarter. Maryland State Retirement & Pension System raised its holdings in U.S. Physical Therapy by 2.2% during the first quarter. Maryland State Retirement & Pension System now owns 5,223 shares of the company’s stock worth $519,000 after acquiring an additional 110 shares in the last quarter. Finally, Everence Capital Management Inc. bought a new stake in U.S. Physical Therapy during the first quarter worth about $207,000. Institutional investors own 97.79% of the company’s stock.

U.S. Physical Therapy Company Profile (Get Rating)

U.S. Physical Therapy, Inc, through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries.

Read More

Get a free copy of the Zacks research report on U.S. Physical Therapy (USPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for U.S. Physical Therapy (NYSE:USPH)

Receive News & Ratings for U.S. Physical Therapy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for U.S. Physical Therapy and related companies with MarketBeat.com's FREE daily email newsletter.